{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T17:48:53Z","timestamp":1778089733736,"version":"3.51.4"},"reference-count":20,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2022,11,11]]},"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:p>A man in his 60s was admitted to the emergency department with chest pain following an intentional overdose of nicorandil and ranolazine. He was known to have an extensive cardiac history and had taken his prescribed medication with suicidal ideation. On presentation, he was hypotensive with a blood pressure of 70\/50\u2009mm Hg despite fluid resuscitation. He was commenced on vasopressor support and transferred to the intensive care unit. Despite an adequate blood pressure on vasopressors, he suffered a ventricular fibrillation cardiac arrest. Return of spontaneous circulation with a Glasgow Coma Score of 15 was achieved following cardiopulmonary resuscitation and three direct current shocks. Following subsequent continuous overnight significant vasopressor dependence, a dose of glucagon was given, and within 2\u2009hours, his vasopressor requirement ceased, maintaining an unsupported normal blood pressure. He remained stable and was subsequently discharged to the coronary care unit for monitoring.<\/jats:p>","DOI":"10.1136\/bcr-2021-245834","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T09:40:25Z","timestamp":1671788425000},"page":"e245834","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Nicorandil and ranolazine overdose management"],"prefix":"10.1136","volume":"15","author":[{"given":"Aziza","family":"Rashid","sequence":"first","affiliation":[{"name":"Intensive Care, Blackpool Fylde and Wyre Hospitals NHS Foundation Trust, Blackpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme","family":"Movio","sequence":"additional","affiliation":[{"name":"School of Medicine, Lancaster University, Lancaster, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma Claire","family":"Lee","sequence":"additional","affiliation":[{"name":"Intensive Care, Blackpool Fylde and Wyre Hospitals NHS Foundation Trust, Blackpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,12,23]]},"reference":[{"key":"2025082801531726000_15.12.e245834.1","unstructured":"TOXBASE\u00ae. Nicorandil. [Online] UK NPIS, 2019. Available: https:\/\/www.toxbase.org\/\/templates\/Public\/Pages\/Toxbase\/ProductPage.aspx?id=77286&epslangua ge=en&print=y [Accessed 1 Jun 2021]."},{"key":"2025082801531726000_15.12.e245834.2","unstructured":"Electronic medicines compendium (emc) . Nicorandil 10mg tablets. [Online] Datapharm Ltd, 2021. Available: https:\/\/www.medicines.org.uk\/emc\/product\/652\/smpc#gref [Accessed 1 Jun 2021]."},{"key":"2025082801531726000_15.12.e245834.3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4103\/0971-9784.148331","article-title":"Intractable hyperkalemia due to nicorandil induced potassium channel syndrome","volume":"18","author":"Chowdhry","year":"2015","journal-title":"Ann Card Anaesth"},{"key":"2025082801531726000_15.12.e245834.4","doi-asserted-by":"crossref","DOI":"10.4103\/ijp.IJP_298_19","article-title":"Nicorandil: a drug with ongoing benefits and different mechanisms in various diseased conditions","volume":"51","author":"Ahmed","year":"2019","journal-title":"Indian J Pharmacol"},{"key":"2025082801531726000_15.12.e245834.5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00005344-199206203-00002","article-title":"Molecular mechanism of action of nicorandil","volume":"20 Suppl 3","author":"Kukovetz","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"key":"2025082801531726000_15.12.e245834.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-007-0612-y"},{"key":"2025082801531726000_15.12.e245834.7","unstructured":"US Food & Drug Administration Ranexa Label, 2015. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/021526s028lbl.pdf [Accessed 1 Jun 2021]."},{"key":"2025082801531726000_15.12.e245834.8","unstructured":"TOXBASE\u00ae. Ranolazine. [Online] UK NPIS, February 2019. Available: https:\/\/www.toxbase.org\/poisons-index-a-z\/r-products\/ranolazine\/ [Accessed 1 Jun 2021]."},{"key":"2025082801531726000_15.12.e245834.9","unstructured":"Reed M , Kernt CC , Gopal S . Ranolazine. StatPearls. [Online] StatPearls Publishing, 2021. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507828 [Accessed 3 Jun 2021]."},{"key":"2025082801531726000_15.12.e245834.10","doi-asserted-by":"crossref","unstructured":"Mehmet A , Ramazan A . Clinical course of a death from ranolazine overdose: a case report. Journal of Emergency Medicine Case Report 2020;11.doi:10.33706\/jemcr.607486","DOI":"10.33706\/jemcr.607486"},{"key":"2025082801531726000_15.12.e245834.11","doi-asserted-by":"crossref","first-page":"1843.e5","DOI":"10.1016\/j.ajem.2015.04.062","article-title":"Ranolazine overdose-induced seizures","volume":"33","author":"Akil","year":"2015","journal-title":"Am J Emerg Med"},{"key":"2025082801531726000_15.12.e245834.12","doi-asserted-by":"publisher","DOI":"10.1136\/emj.20.1.98"},{"key":"2025082801531726000_15.12.e245834.13","unstructured":"Drug Bank Database Ranolazine. [Online] \u00a9 OMx Personal Health Analytics, Inc, 2021 [Accessed 3 Jun 2021]."},{"key":"2025082801531726000_15.12.e245834.14","doi-asserted-by":"publisher","DOI":"10.1081\/CLT-120023761"},{"key":"2025082801531726000_15.12.e245834.15","doi-asserted-by":"crossref","unstructured":"Boyd R . Ghosh A Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. 20. Glucagon for the treatment of symptomatic beta blocker overdose: Emerg Med Journal, 2003.","DOI":"10.1136\/emj.20.5.464"},{"key":"2025082801531726000_15.12.e245834.16","first-page":"S411","article-title":"Adrenaline and noradrenaline increases contractile force of human ventricle through both beta 1- and beta 2-adrenoreceptors","volume":"46","author":"Kaumann","year":"1987","journal-title":"Biomed Biochem Acta"},{"key":"2025082801531726000_15.12.e245834.17","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-018-0791-z","article-title":"Does glucagon have a positive inotropic effect in the human heart?","volume":"17","author":"Hern\u00e1ndez-Cascales","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"2025082801531726000_15.12.e245834.18","doi-asserted-by":"publisher","DOI":"10.1253\/jcj.63.610"},{"key":"2025082801531726000_15.12.e245834.19","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200645050-00003"},{"key":"2025082801531726000_15.12.e245834.20","article-title":"Ranolazine overdose","volume":"46","author":"Ngo","year":"2008","journal-title":"Journal of Toxicology"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-245834","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:53:26Z","timestamp":1756371206000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-245834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":20,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,23]]},"published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1136\/bcr-2021-245834"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-245834","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}